Trial Profile

Tarlatamab in Advanced DLL3-Expressing Tumors Including Neuroendocrine Neoplasms

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 24 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tarlatamab (Primary)
Indications Carcinoma; Gastrointestinal cancer; Neuroendocrine carcinoma; Pancreatic cancer; Small cell lung cancer
Focus Therapeutic Use

Most Recent Events

25 Mar 2025 Planned initiation date changed from 1 Apr 2025 to 21 Mar 2025.
25 Mar 2025 Status changed from not yet recruiting to recruiting.
17 Mar 2025 Planned End Date changed from 24 Sep 2029 to 24 Apr 2029.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com